Clinical Trials Browser

Phase 1 × Adenocarcinoma × 30 days × Clear all

NCT04644770 2026-03-13

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Phase 1 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT05873686 2026-03-03

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Phase 1 Recruiting

GenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Mesothelioma, Neoplasms